엑세스바이오 Stock: price and insider trades · South Korea
No insider purchase over the last 90 days. The latest, by 박희덕, was filed 29 Jan 2026.
엑세스바이오: what insiders have been doing
엑세스바이오, classified in the Health Care sector, is a listed company. Its insiders report their share dealings to DART (FSS). 4 insiders have disclosed 4 filings since 1 November 2025.
Every open-market trade in the period is a purchase: 3 purchases, from 3 insiders, and not a single sale. The totals do not cover 3 filings with an undisclosed amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. On the buying side, the filings list 2 board members among the declarants.
The last insider purchase was made public on 29 January 2026, 285 days ago.
For context, the typical company on the same exchange (median of 2,655 companies) published 7 filings over the same period, against 4 filings here. Looking back to 2022, when coverage begins, insiders filed 4 purchases and 1 sale.
For comparison within the same sector, see the insider buying recorded at Dynavox Group AB and UCB. This summary is built from DART (FSS) disclosures alone and does not predict where the share price will go.
Who traded when
BuySaleFinancial data
· cache
- ●Executives0DART
- 7,776 sharesKRXDART:20260129000727Canonical exit: 12 Jan 2026 (T+90)
- 6,276 sharesShareKRXDART:20260129000722Canonical exit: 29 Apr 2026 (T+90)
- 1,500 sharesShareKRXDART:20260129000716Canonical exit: 29 Apr 2026 (T+90)
- 57,937 sharesKRXDART:20250407003942Canonical exit: 29 Jun 2025 (T+90)
- ●Executives0DART
- 61,169 sharesKRXDART:20241211000388
- ●Executives0DART
- ●Executives0DART
- ●Executives0DART
10 of 10 declarations
About 엑세스바이오
Access Bio is in the health and pharmaceutical sector, listed on the XKRX market. The company specializes in the development of medical diagnostics and health technologies.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
